Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on assets-26.4%-2.5pp-23.8%+10.7pp-34.6%+46.2pp-80.7%+1.8pp-82.5%-17.2pp
Liquidity
Current ratio23.8×+1.4×22.4×+5.4×16.9×-10.5×27.4×-2.6×30×+1.1×
Quick ratio23.8×+1.4×22.4×+5.4×16.9×-10.5×27.4×-2.6×30×+1.1×
Cash ratio-0.1×3.1×-1.3×4.4×-1.0×5.4×-1.7×7.1×+2.4×
Leverage
Debt-to-equity0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Valuation
Market capitalization$2.43B+65.6%$1.47B+57.7%$930.43M
Enterprise value$2.38B+67.5%$1.42B+69.1%$841.09M
Price / book+1.9×3.1×+1.2×1.9×
Free cash flow yield-3.8%
Earnings yield-4.8%+2.4pp-7.2%+10.0pp-17.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Oruka Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Oruka Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.